Welcome to our dedicated page for Innoviva SEC filings (Ticker: INVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Innoviva, Inc. (NASDAQ: INVA) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including Forms 10-K, 10-Q, 8-K, and other documents filed with the U.S. Securities and Exchange Commission. Innoviva is a diversified healthcare holding company with a royalties portfolio linked to GSK respiratory products, a critical care and infectious disease platform operated through Innoviva Specialty Therapeutics, and a portfolio of strategic healthcare investments.
In its SEC reports, Innoviva discusses royalty revenue from RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®, net product sales from therapies such as GIAPREZA®, XERAVA®, XACDURO®, and ZEVTERA®, and the performance of its strategic investment portfolio. Current reports on Form 8-K, for example, furnish quarterly earnings press releases that detail revenue composition, income from operations, changes in fair values of equity and long-term investments, and balance sheet metrics.
For investors following Innoviva’s infectious disease and critical care focus, periodic filings also provide context on regulatory milestones and development programs, such as the New Drug Application for zoliflodacin and its QIDP designation. Proxy statements and related documents can offer additional insight into governance, equity compensation, and capital allocation policies, while registration statements and prospectuses may describe financing activities.
On Stock Titan, each Innoviva filing is accompanied by AI-powered summaries designed to highlight key points, such as changes in royalty streams, trends in IST net product sales, significant investments or licensing transactions, and updates to risk factors. Users can quickly scan recent 10-Q and 10-K reports, review 8-K announcements, and examine Form 4 insider transaction filings to understand how executives and directors are trading INVA shares. Real-time integration with EDGAR helps ensure that new Innoviva filings appear promptly, while AI-generated overviews make dense regulatory documents more accessible to both individual and professional investors.
Franklin Resources, Inc. and its principals Charles B. Johnson and Rupert H. Johnson, Jr. filed Amendment No. 2 to Schedule 13G on 08/01/2025 covering Innoviva, Inc. (INVA) common stock as of 06/30/2025.
- Ownership: 2,827,918 shares beneficially owned, equal to 4.5 % of outstanding shares.
- Control: Sole voting power – 2,583,688 shares; sole dispositive power – 2,827,918 shares; no shared voting or dispositive power.
- Threshold change: Item 5 confirms ownership has fallen to “5 percent or less,” indicating the group is now below the 5 % reporting threshold.
- Reporting persons: Franklin Resources (DE), Charles B. Johnson, and Rupert H. Johnson, Jr.; all file as holding company/control persons (Type HC, CO/IN).
- Purpose: Securities are held in the ordinary course by investment‐management subsidiaries; the filing states no intent to influence control of Innoviva.
The amendment mainly updates share counts and affirms that the institutional investor’s aggregate stake has decreased to a non-activist, sub-5 % level.